NO953781L - Terapeutisk anvendelse av keratinocyttvekstfaktor - Google Patents

Terapeutisk anvendelse av keratinocyttvekstfaktor

Info

Publication number
NO953781L
NO953781L NO953781A NO953781A NO953781L NO 953781 L NO953781 L NO 953781L NO 953781 A NO953781 A NO 953781A NO 953781 A NO953781 A NO 953781A NO 953781 L NO953781 L NO 953781L
Authority
NO
Norway
Prior art keywords
growth factor
kgf
therapeutic application
keratinocyte growth
vivo
Prior art date
Application number
NO953781A
Other languages
English (en)
Other versions
NO953781D0 (no
Inventor
Glenn F Pierce
Regina M Housley
Charles F Morris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO953781(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO953781D0 publication Critical patent/NO953781D0/no
Publication of NO953781L publication Critical patent/NO953781L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Basert på omfattende under-søkelser ln vivo hos dyr, er det nå blitt oppdaget at KGF stimulerer proli-ferasjon, vekst og differensiering av forskjellige celler i epitelvev, i til-legg til•keratinocytter. Denne bedre forståelsen av de biologiske effektene av KGF in vivo muliggjør bruken av dette polypeptidet som et terapeutisk middel, passende formulert i et farma-søytisk preparat, til den spesifikke behandling av sykdomstilstander og medisinske tilstander som angriper vev og organer, slik som hudtilknytninger, lever, lunge og mave- og tarmkanal.
NO953781A 1993-03-26 1995-09-25 Terapeutisk anvendelse av keratinocyttvekstfaktor NO953781L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4074293A 1993-03-26 1993-03-26
PCT/US1994/003208 WO1994023032A1 (en) 1993-03-26 1994-03-24 Therapeutic uses of keratinocyte growth factor

Publications (2)

Publication Number Publication Date
NO953781D0 NO953781D0 (no) 1995-09-25
NO953781L true NO953781L (no) 1995-11-27

Family

ID=21912689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953781A NO953781L (no) 1993-03-26 1995-09-25 Terapeutisk anvendelse av keratinocyttvekstfaktor

Country Status (23)

Country Link
EP (1) EP0619370B1 (no)
JP (1) JP3578761B2 (no)
KR (1) KR100390340B1 (no)
CN (1) CN1064710C (no)
AT (1) ATE183233T1 (no)
AU (1) AU707340B2 (no)
CA (1) CA2159109C (no)
CZ (1) CZ285996B6 (no)
DE (1) DE69419958T2 (no)
DK (1) DK0619370T3 (no)
ES (1) ES2136673T3 (no)
FI (1) FI954541A (no)
GR (1) GR3031509T3 (no)
HU (1) HU220641B1 (no)
IL (4) IL137581A (no)
NO (1) NO953781L (no)
NZ (1) NZ263967A (no)
RU (1) RU2146148C1 (no)
SG (1) SG49841A1 (no)
SI (1) SI0619370T1 (no)
SK (1) SK281674B6 (no)
UA (1) UA46706C2 (no)
WO (1) WO1994023032A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
EP0785948B1 (en) * 1994-10-13 2003-04-16 Amgen Inc., Analogs of keratinocyte growth factor
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
DK0815115T3 (da) * 1995-02-14 2003-09-15 Human Genome Sciences Inc Keratinocytvækstfaktor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
PT1486565E (pt) * 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
EP1452205B1 (en) * 1996-10-15 2007-11-28 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ES2297286T3 (es) * 1996-10-15 2008-05-01 Amgen Inc. Uso de productos proteicos del factor de crecimiento de queratinocitos-2.
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6228839B1 (en) * 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
NZ505324A (en) 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6599879B1 (en) 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
EP1276496B1 (en) * 2000-03-20 2005-06-15 Pfizer Products Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
PL362397A1 (en) * 2001-02-06 2004-11-02 Merck Patent Gmbh Modified keratinocyte growth factor (kgf) with reduced immunogenicity
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
JP2008512435A (ja) * 2004-09-13 2008-04-24 ユニバーシティ、オブ、サウサンプトン 喘息の成長因子治療
CN101822821B (zh) * 2010-04-27 2013-01-23 复旦大学附属中山医院 角质细胞生长因子-2在制备防治肺损伤的药物中的应用
CN104707164B (zh) * 2015-03-31 2017-01-18 中国人民解放军军事医学科学院基础医学研究所 一种复合壳聚糖水凝胶敷料及其制备方法和应用
CN106226511B (zh) * 2016-07-28 2018-04-06 苏州金盟生物技术有限公司 一种重组人角质细胞生长因子生物学活性检测方法
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
EP3888625A4 (en) 2018-11-27 2022-10-05 Jellyfish Research Laboratories, Inc. COMPOSITION FOR SCALP AND HAIR
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) * 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用

Also Published As

Publication number Publication date
HUT72711A (en) 1996-05-28
HU9502800D0 (en) 1995-12-28
HU220641B1 (hu) 2002-03-28
JP3578761B2 (ja) 2004-10-20
IL109122A (en) 2004-07-25
EP0619370A1 (en) 1994-10-12
CZ285996B6 (cs) 1999-12-15
CA2159109C (en) 2004-11-16
FI954541A (fi) 1995-11-23
ATE183233T1 (de) 1999-08-15
KR960701204A (ko) 1996-02-24
JP2002526026A (ja) 2002-08-13
GR3031509T3 (en) 2000-01-31
RU2146148C1 (ru) 2000-03-10
CN1217022A (zh) 1999-05-19
CZ248295A3 (en) 1996-12-11
IL109122A0 (en) 1994-06-24
ES2136673T3 (es) 1999-12-01
DE69419958T2 (de) 2000-04-20
IL137581A (en) 2009-09-01
FI954541A0 (fi) 1995-09-25
NO953781D0 (no) 1995-09-25
SG49841A1 (en) 1998-06-15
SK281674B6 (sk) 2001-06-11
NZ263967A (en) 2005-02-25
AU707340B2 (en) 1999-07-08
IL161568A0 (en) 2004-09-27
EP0619370B1 (en) 1999-08-11
AU6524394A (en) 1994-10-24
CA2159109A1 (en) 1994-10-13
WO1994023032A1 (en) 1994-10-13
SI0619370T1 (en) 1999-10-31
DK0619370T3 (da) 2000-02-28
SK118595A3 (en) 1996-11-06
KR100390340B1 (ko) 2003-09-26
UA46706C2 (uk) 2002-06-17
CN1064710C (zh) 2001-04-18
IL137581A0 (en) 2001-07-24
DE69419958D1 (de) 1999-09-16

Similar Documents

Publication Publication Date Title
NO953781L (no) Terapeutisk anvendelse av keratinocyttvekstfaktor
Ferguson et al. Scar formation: the spectral nature of fetal and adult wound repair
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
FR2644066B1 (fr) Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
DE69738336D1 (de) Verwendung von keratinocyte growth factor-2
ATE428438T1 (de) Tcf-ii enthaltende medizinische zusammensetzung
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
Klein Modulation of cutaneous wound healing mechanisms to affect characteristics of healing
ATE357520T1 (de) Biologisches material zur behandlung eines säugetieres durch transfer einesfür einen antikörper kodierendes gen und eine pharmazeutische zusammensetzungdie diese enthält
TH41485A (th) วิธีสำหรับรักษาภาวะการแข็งตัวของเลือดเกินหรือภาวะการพร่องโปรตีนชีที่ได้รับภายหลัง

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application